Balance Sheet
Cash Flow Statement
AmortizationAmortization of Deferred ChargesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Amortization (2023 - 2025)

Historic Amortization for BioLineRx (BLRX) over the last 3 years, with Q1 2025 value amounting to -$7.7 million.

  • BioLineRx's Amortization rose 4245.88% to -$7.7 million in Q1 2025 from the same period last year, while for Mar 2025 it was -$7.7 million, marking a year-over-year change of. This contributed to the annual value of -$34.7 million for FY2024, which is 19117.51% down from last year.
  • As of Q1 2025, BioLineRx's Amortization stood at -$7.7 million, which was up 4245.88% from -$5.4 million recorded in Q4 2024.
  • In the past 5 years, BioLineRx's Amortization ranged from a high of $18.9 million in Q4 2023 and a low of -$13.4 million during Q1 2024
  • In the last 3 years, BioLineRx's Amortization had a median value of -$5.4 million in 2024 and averaged -$706600.0.
  • As far as peak fluctuations go, BioLineRx's Amortization crashed by 42351.66% in 2024, and later soared by 4245.88% in 2025.
  • Quarter analysis of 3 years shows BioLineRx's Amortization stood at $18.9 million in 2023, then crashed by 128.73% to -$5.4 million in 2024, then crashed by 42.32% to -$7.7 million in 2025.
  • Its Amortization stands at -$7.7 million for Q1 2025, versus -$5.4 million for Q4 2024 and -$13.4 million for Q1 2024.